These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 21733757

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY, Constantinescu CS.
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [Abstract] [Full Text] [Related]

  • 23. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis.
    Goodin DS.
    Neuroepidemiology; 1999 Apr; 18(2):53-63. PubMed ID: 10023128
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP, Vermersch P.
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [Abstract] [Full Text] [Related]

  • 27. Emerging multiple sclerosis oral therapies.
    Rammohan KW, Shoemaker J.
    Neurology; 2010 Jan 05; 74 Suppl 1():S47-53. PubMed ID: 20038763
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P, Stelmasiak Z.
    Neurol Neurochir Pol; 1995 Jan 05; 29(1):69-76. PubMed ID: 7596480
    [Abstract] [Full Text] [Related]

  • 29. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
    Claussen MC, Korn T.
    Clin Immunol; 2012 Jan 05; 142(1):49-56. PubMed ID: 21367665
    [Abstract] [Full Text] [Related]

  • 30. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A, D'Souza M, Kappos L, Yaldizli O.
    Expert Opin Investig Drugs; 2010 Dec 05; 19(12):1603-12. PubMed ID: 21067468
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
    Laugel B, Borlat F, Galibert L, Vicari A, Weissert R, Chvatchko Y, Bruniquel D.
    J Neuroimmunol; 2011 Dec 15; 240-241():52-7. PubMed ID: 22035961
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 15; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 37. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S.
    Drug Saf; 2020 Jul 15; 43(7):635-643. PubMed ID: 32447743
    [Abstract] [Full Text] [Related]

  • 38. [Combined therapy in multiple sclerosis].
    García-Merino JA, Blasco-Quítez MR, Ortiz-Benítez P, Puerta C.
    Rev Neurol; 2020 Jul 15; 36(6):545-9. PubMed ID: 12652419
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.